These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Production and characterisation of a C595 antibody-99mTc conjugate for immunoscintigraphy of bladder cancer. Simms MS; Murray A; Denton G; Scholfield DP; Price MR; Perkins AC; Bishop MC Urol Res; 2001 Feb; 29(1):13-9. PubMed ID: 11310209 [TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Hughes OD; Bishop MC; Perkins AC; Frier M; Price MR; Denton G; Smith A; Rutherford R; Schubiger PA Eur J Nucl Med; 1997 Apr; 24(4):439-43. PubMed ID: 9096097 [TBL] [Abstract][Full Text] [Related]
5. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. Hughes OD; Bishop MC; Perkins AC; Wastie ML; Denton G; Price MR; Frier M; Denley H; Rutherford R; Schubiger PA J Clin Oncol; 2000 Jan; 18(2):363-70. PubMed ID: 10637251 [TBL] [Abstract][Full Text] [Related]
6. Targeting of bladder cancer with monoclonal antibody NCRC48--a possible approach for intravesical therapy. Kunkler RB; Bishop MC; Green DJ; Pimm MV; Price MR; Frier M Br J Urol; 1995 Jul; 76(1):81-6. PubMed ID: 7648066 [TBL] [Abstract][Full Text] [Related]
7. Tumour imaging of bladder carcinomas and their metastases with 111indium-labelled monoclonal anti-CEA antibody BW 431/26. Boeckmann W; Baum RP; Schuldes H; Kramer W; Hertel A; Baew-Christow T; Hanke P; Jonas D; Hör G Br J Cancer Suppl; 1990 Jul; 10():81-4. PubMed ID: 2383485 [TBL] [Abstract][Full Text] [Related]
8. Production and characterization of 188Re-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. Murray A; Simms MS; Scholfield DP; Vincent RM; Denton G; Bishop MC; Price MR; Perkins AC J Nucl Med; 2001 May; 42(5):726-32. PubMed ID: 11337567 [TBL] [Abstract][Full Text] [Related]
9. MUC1 mucin as a tumour marker in bladder cancer. Simms MS; Hughes OD; Limb M; Price MR; Bishop MC BJU Int; 1999 Aug; 84(3):350-2. PubMed ID: 10468735 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Wang L; Chen H; Liu F; Madigan MC; Power CA; Hao J; Patterson KI; Pourgholami MH; O'Brien PM; Perkins AC; Li Y Cancer Lett; 2011 Jan; 300(2):122-33. PubMed ID: 21075513 [TBL] [Abstract][Full Text] [Related]
11. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer. Croce MV; Isla-Larrain MT; Rua CE; Rabassa ME; Gendler SJ; Segal-Eiras A J Histochem Cytochem; 2003 Jun; 51(6):781-8. PubMed ID: 12754289 [TBL] [Abstract][Full Text] [Related]
12. Mucin expression by transitional cell carcinomas of the bladder. Walsh MD; Hohn BG; Thong W; Devine PL; Gardiner RA; Samaratunga ML; McGuckin MA Br J Urol; 1994 Mar; 73(3):256-62. PubMed ID: 8162502 [TBL] [Abstract][Full Text] [Related]
13. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732 [TBL] [Abstract][Full Text] [Related]
14. Immunoscintigraphy of colorectal cancer with an antibody to epithelial membrane antigen (EMA). Yiu CY; Baker LA; Davidson BR; Ward M; Roberts K; Clarke G; Ward C; Westwood J; Boulos PB; Clark CG Dis Colon Rectum; 1990 Feb; 33(2):122-6. PubMed ID: 2404713 [TBL] [Abstract][Full Text] [Related]
15. Tissue and serum MUC1 mucin detection in breast cancer patients. Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915 [TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
18. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Qu CF; Li Y; Song YJ; Rizvi SM; Raja C; Zhang D; Samra J; Smith R; Perkins AC; Apostolidis C; Allen BJ Br J Cancer; 2004 Dec; 91(12):2086-93. PubMed ID: 15599383 [TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. Shanehsazzadeh S; Gruettner C; Lahooti A; Mahmoudi M; Allen BJ; Ghavami M; Daha FJ; Oghabian MA Contrast Media Mol Imaging; 2015; 10(3):225-36. PubMed ID: 25327822 [TBL] [Abstract][Full Text] [Related]
20. Immunoscintigraphy of colorectal cancer using a monoclonal antibody 77-1. Yiu CY; Baker LA; Davidson BR; McCready VR; Boulos PB Eur J Surg Oncol; 1991 Oct; 17(5):495-501. PubMed ID: 1936297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]